A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer
Importance Four assays registered with the US Food and Drug Administration (FDA) detect
programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti–programmed
cell death 1 and anti–PD-L1 therapies. The tests use 4 separate PD-L1 antibodies on 2
separate staining platforms and have their own scoring systems, which raises questions
about their similarity and the potential interchangeability of the tests. Objective To compare
the performance of 4 PD-L1 platforms, including 2 FDA-cleared assays, 1 test for …
programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti–programmed
cell death 1 and anti–PD-L1 therapies. The tests use 4 separate PD-L1 antibodies on 2
separate staining platforms and have their own scoring systems, which raises questions
about their similarity and the potential interchangeability of the tests. Objective To compare
the performance of 4 PD-L1 platforms, including 2 FDA-cleared assays, 1 test for …